208 related articles for article (PubMed ID: 38300480)
21. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
Roque A; Odia Y
CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapies in the medical management of craniopharyngioma.
Iglesias P
Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
[TBL] [Abstract][Full Text] [Related]
23. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
[No Abstract] [Full Text] [Related]
24. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
Erfurth EM
J Intern Med; 2023 Sep; 294(3):269-280. PubMed ID: 37424210
[TBL] [Abstract][Full Text] [Related]
25. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
Brastianos PK; Santagata S
Eur J Endocrinol; 2016 Apr; 174(4):R139-44. PubMed ID: 26563980
[TBL] [Abstract][Full Text] [Related]
26. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
[TBL] [Abstract][Full Text] [Related]
27. Craniopharyngiomas.
Hamblin R; Tsermoulas G; Karavitaki N
Presse Med; 2021 Dec; 50(4):104078. PubMed ID: 34688870
[TBL] [Abstract][Full Text] [Related]
28. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Hengartner AC; Prince E; Vijmasi T; Hankinson TC
Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
[TBL] [Abstract][Full Text] [Related]
29. The Medical Therapy of Craniopharyngiomas: The Way Ahead.
Alexandraki KI; Kaltsas GA; Karavitaki N; Grossman AB
J Clin Endocrinol Metab; 2019 Dec; 104(12):5751-5764. PubMed ID: 31369091
[TBL] [Abstract][Full Text] [Related]
30. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
[TBL] [Abstract][Full Text] [Related]
31. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
[No Abstract] [Full Text] [Related]
32. Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms.
Bartels S; Adisa A; Aladelusi T; Lemound J; Stucki-Koch A; Hussein S; Kreipe H; Hartmann C; Lehmann U; Hussein K
Virchows Arch; 2018 Jun; 472(6):1055-1059. PubMed ID: 29546640
[TBL] [Abstract][Full Text] [Related]
33. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Martinez NL; Khanna O; Farrell CJ
Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
[TBL] [Abstract][Full Text] [Related]
34. [Etiology, Genetic Features and Clinical Presentations in Craniopharyngiomas].
Horiguchi K
No Shinkei Geka; 2023 Jul; 51(4):607-614. PubMed ID: 37491057
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
[TBL] [Abstract][Full Text] [Related]
36. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
[TBL] [Abstract][Full Text] [Related]
37. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts.
Schweizer L; Capper D; Hölsken A; Fahlbusch R; Flitsch J; Buchfelder M; Herold-Mende C; von Deimling A; Buslei R
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):733-42. PubMed ID: 25442675
[TBL] [Abstract][Full Text] [Related]
38. BRAF plus MEK inhibition effective in papillary craniopharyngioma.
Sidaway P
Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37491596
[No Abstract] [Full Text] [Related]
39. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
[TBL] [Abstract][Full Text] [Related]
40. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]